Published in:
01-02-2017 | Erratum
Erratum to: Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature
Published in: Immunologic Research | Issue 1/2017
Login to get accessExcerpt
The original version of this article unfortunately contained a mistake. It has been corrected with this erratum. And the original article was also corrected.
1.
The co-corresponding author of the article is Dr. Dimitri Poddighe (dimimedpv@yahoo.it).
2.
Prof. Beniamino Palmieri and Dr. Dimitri Poddighe contributed equally to the drafting and writing of this study.
Table 3
Description of ADRs related to HPV immunization
|
After first dose
|
After second dose
|
After third dose
|
|
|---|---|---|---|
|
Symptoms (within 5 days post-vaccination)
|
|||
|
Injection site reactions
|
|||
|
Pain
|
2
|
2
|
1
|
|
Uncontrollable and involuntary movement of the limb
|
1
|
||
|
Swelling
|
1
|
1
|
|
|
Systemic reactions
|
|||
|
Low-grade fever
|
3
|
5
|
1
|
|
Headache
|
5
|
5
|
2
|
|
Recurrent syncope
|
4
|
3
|
|
|
Persistent convulsive hunger
|
1
|
||
|
Irritability
|
1
|
2
|
|
|
Epileptic seizures
|
1
|
||
|
Temporary speech loss
|
1
|
||
|
Lower limbs paraesthesia and paresis
|
1
|
||
|
Hot flushes
|
1
|
||
|
Severe stomach pain
|
2
|
1
|
1
|
|
Insomnia
|
3
|
2
|
|
|
Hypersensitivity reactions
|
1
|
||
|
Leg muscle pain (myalgia)
|
1
|
3
|
1
|
|
Gait and orthostatic posture impairment
|
1
|
||
|
Excessive sweating
|
1
|
||
|
Vomiting
|
1
|
||
|
Symptoms (5–15 days post-vaccination)
|
|||
|
Systemic reactions
|
|||
|
Asthenia
|
2
|
5
|
1
|
|
Persistent thirst
|
3
|
||
|
Severe hands and feet itching
|
1
|
||
|
Optic neuritis
|
1
|
||
|
Symptoms (15–20 days post-vaccination)
|
|||
|
Systemic reactions
|
|||
|
Amenorrhoea
|
1
|
||
|
Skin rashes
|
1
|
1
|
|
|
Tachycardia
|
1
|
1
|
|
|
Difficult breathing
|
1
|
||
|
Weight loss
|
1
|
||
Table 5
Proposed diagnostic criteria of autoimmune/inflammatory syndrome induced by adjuvants (ASIA)
|
Major criteria
|
|
Previous exposure to an external stimulus (i.e. vaccine, adjuvant, silicone, nucleic acids, fragments of bacterial cell walls)
|
|
One of the following “typical” manifestations:
|
|
Myalgia/myositis, muscle weakness
|
|
Arthralgia and/or arthritis
|
|
Chronic fatigue, non-refreshing sleep or sleep disturbances
|
|
Neurological manifestations (especially if associated with demyelination)
|
|
Memory loss and cognitive impairment
|
|
Fever
|
|
Dry mouth
|
|
Improvement of symptoms after the removal of the triggering agent
|
|
Typical biopsy of the involved organs
|
|
Minor criteria
|
|
Appearance of autoantibodies or autoantibodies directed against the suspected adjuvant
|
|
Other clinical manifestations (i.e. functional somatic syndromes)
|
|
Association with specific HLA haplotypes (i.e. HLA-DRB1, HLA-DQB1)
|
|
Development of autoimmune diseases
|
|
Diagnostic requirements:
|
|
Two major criteria
|
|
One major criteria + two minor criteria
|